
ICYMI: Top Highlights From AMCP Nexus 2022
The
Here are some of the highlights of AMCP Nexus 2022.
Recent federal legislative and regulatory updates in managed care pharmacy have prioritized topics ranging from expedited access to novel therapeutics to the health disparities and equity concerns affecting patient populations nationwide, but progress on these developments will depend on the impact of the upcoming midterm elections, according to stakeholders of a panel discussion.
Oncology represents more than a third of specialty drugs in the pipeline with substantial growth seen in recent years for clinical development and accelerated approvals. But rising cost of these new and emerging therapeutics continues to have major implications for managed care stakeholders, according to experts of the concluding keynote session.
Two posters addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the efficacy of adjuvant lenacapavir in treatment-naïve patients.
Panelists discussed enhanced utilization management strategies to manage the rising cost of specialty drugs, while providing members with support for rare, complex conditions.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.